ArticleFrontiers in pediatrics2026

Omalizumab demonstrates efficacy and safety in Chinese children under 12 with chronic urticaria: a case series.

Hui Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.